MA31918B1 - Agents et épitopes de liaison à wise - Google Patents

Agents et épitopes de liaison à wise

Info

Publication number
MA31918B1
MA31918B1 MA32918A MA32918A MA31918B1 MA 31918 B1 MA31918 B1 MA 31918B1 MA 32918 A MA32918 A MA 32918A MA 32918 A MA32918 A MA 32918A MA 31918 B1 MA31918 B1 MA 31918B1
Authority
MA
Morocco
Prior art keywords
wise
agents
epiopes
connection
manufacture
Prior art date
Application number
MA32918A
Other languages
Arabic (ar)
English (en)
French (fr)
Inventor
Xueming Qian
Kevin Graham
Grant Shimamoto
Barbara S Tipton
Mei-Mei Tsai
Aaron George Winters
Li Zhang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA31918B1 publication Critical patent/MA31918B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA32918A 2007-11-21 2010-06-15 Agents et épitopes de liaison à wise MA31918B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21
PCT/US2008/012987 WO2009070243A2 (en) 2007-11-21 2008-11-21 Wise binding agents and epitopes

Publications (1)

Publication Number Publication Date
MA31918B1 true MA31918B1 (fr) 2010-12-01

Family

ID=40524859

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32918A MA31918B1 (fr) 2007-11-21 2010-06-15 Agents et épitopes de liaison à wise

Country Status (17)

Country Link
US (2) US8043620B2 (cg-RX-API-DMAC7.html)
EP (1) EP2220118A2 (cg-RX-API-DMAC7.html)
JP (2) JP5583591B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100099193A (cg-RX-API-DMAC7.html)
CN (1) CN101925611A (cg-RX-API-DMAC7.html)
AU (1) AU2008330125B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820387A2 (cg-RX-API-DMAC7.html)
CA (1) CA2705879A1 (cg-RX-API-DMAC7.html)
CO (1) CO6311002A2 (cg-RX-API-DMAC7.html)
CR (1) CR11523A (cg-RX-API-DMAC7.html)
EA (1) EA201000844A1 (cg-RX-API-DMAC7.html)
IL (1) IL205569A0 (cg-RX-API-DMAC7.html)
MA (1) MA31918B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010005656A (cg-RX-API-DMAC7.html)
TN (1) TN2010000213A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009070243A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201003578B (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005266875B2 (en) 2004-07-23 2012-07-26 Acceleron Pharma Inc. ActRII receptor polypeptides, methods and compositions
CN105001320A (zh) 2005-11-23 2015-10-28 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CN101835485B (zh) 2007-02-01 2016-10-26 阿塞勒隆制药公司 活化素-actriia拮抗剂及在治疗或预防乳腺癌中的用途
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
JP5574711B2 (ja) 2007-02-09 2014-08-20 アクセルロン ファーマ， インコーポレイテッド 癌患者における骨成長を促進するためのアクチビン−ａｃｔｒｉｉａアンタゴニストおよびその使用
EP3243524A1 (en) 2007-09-18 2017-11-15 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
WO2010019261A1 (en) 2008-08-14 2010-02-18 Acceleron Pharma Inc. Use of gdf traps to increase red blood cell levels
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2387412A4 (en) 2009-01-13 2013-04-03 Acceleron Pharma Inc PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
BRPI1010704B1 (pt) 2009-06-12 2021-12-14 Acceleron Pharma Inc Polipeptídeo recombinante, proteína de fusão recombinante, preparação farmacêutica e uso da mesma
WO2011025964A2 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
JP6267425B2 (ja) 2009-11-17 2018-01-24 アクセルロン ファーマ， インコーポレイテッド 筋ジストロフィー治療のためのユートロフィン誘導に関するａｃｔｒｉｉｂタンパク質およびその改変体およびその使用
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2507381A4 (en) * 2009-12-04 2016-07-20 Hoffmann La Roche MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS AND METHODS
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
BR112012021941A2 (pt) * 2010-03-02 2022-02-01 Abbvie Inc Proteínas terapêuticas de ligação a dll4
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
AU2012327223A1 (en) 2011-11-30 2013-06-20 Wellstat Diagnostics, Llc. Assays, antibodies, immunogens and compositions related to 5-FU
WO2013103800A1 (en) * 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
EP2904015A4 (en) 2012-10-02 2016-10-05 Univ Rutgers TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS
NZ707477A (en) 2012-11-02 2019-09-27 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders
BR112015010360A8 (pt) 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
AU2014315081A1 (en) 2013-09-05 2016-03-24 Duke University Nav1.7 antibodies and methods of using the same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
AP2017009674A0 (en) 2014-06-13 2017-01-31 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
UA122673C2 (uk) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Антитіло, що специфічно зв'язується з людським il-6
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
JP2019510078A (ja) 2016-02-23 2019-04-11 セセン バイオ， インコーポレイテッド Ｉｌ−６アンタゴニスト製剤およびその使用
CA3017958C (en) 2016-03-18 2024-03-12 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
EP3448875A4 (en) * 2016-04-29 2020-04-08 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018129248A1 (en) * 2017-01-06 2018-07-12 The Regents Of The University Of California Therapeutic anti-ige antibodies and methods and compositions thereof
US11021540B2 (en) * 2017-09-07 2021-06-01 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
KR20220034176A (ko) * 2019-07-12 2022-03-17 고쿠리츠 다이가쿠 호진 교토 다이가쿠 치아의 재생 치료를 위한 usag-1을 표적 분자로 한 중화 항체
CN112180099B (zh) * 2020-09-15 2022-07-29 江南大学附属医院 子宫内膜异位症血清标志物的应用
IL314524A (en) 2022-01-28 2024-09-01 Georgiamune Inc Antibodies to programmed cell death protein 1 that are agonists for PD-1
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003276430A1 (en) * 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
MXPA06010887A (es) * 2004-03-23 2007-03-08 Amgen Inc Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano.
PL3345607T3 (pl) * 2006-12-29 2023-01-09 Ossifi-Mab Llc Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise
WO2008156712A1 (en) * 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2010131185A1 (en) * 2009-05-12 2010-11-18 Pfizer Inc. Blocking anti-dkk-1 antibodies and their uses

Also Published As

Publication number Publication date
WO2009070243A3 (en) 2009-10-29
ZA201003578B (en) 2011-04-28
CA2705879A1 (en) 2009-06-04
IL205569A0 (en) 2010-12-30
TN2010000213A1 (en) 2011-11-11
WO2009070243A2 (en) 2009-06-04
JP2011504501A (ja) 2011-02-10
BRPI0820387A2 (pt) 2015-05-26
JP2014167002A (ja) 2014-09-11
CN101925611A (zh) 2010-12-22
EA201000844A1 (ru) 2011-10-31
MX2010005656A (es) 2010-11-12
US20090130114A1 (en) 2009-05-21
US20120003237A1 (en) 2012-01-05
AU2008330125B2 (en) 2012-11-22
US8043620B2 (en) 2011-10-25
US8309092B2 (en) 2012-11-13
JP5583591B2 (ja) 2014-09-03
KR20100099193A (ko) 2010-09-10
CO6311002A2 (es) 2011-08-22
EP2220118A2 (en) 2010-08-25
AU2008330125A1 (en) 2009-06-04
CR11523A (es) 2010-12-16

Similar Documents

Publication Publication Date Title
MA31918B1 (fr) Agents et épitopes de liaison à wise
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA32190B1 (fr) Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 et leur utilisation
MY152503A (en) 4-phenyl-pyrane-3, 5-diones, 4-phenyl-thiopyrane-3, 5-diones and cyclohexanetriones as novel herbicides
PT2040755E (pt) Combinação de um inibidor de colinesterase e um composto com afinidade para o receptor 5-ht6
EA200701918A1 (ru) Белок липокалин
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
UA101346C2 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и 2-фенилциклогексан-1,3,5-трионы как гербициды
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
GB2453058A (en) Kinase antagonists
AU2010246102A8 (en) Pesticidal compositions
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
TW200732349A (en) Anti-OX40L antibodies and methods using same
BRPI0816767A2 (pt) 1'3'-dissubstituída-4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'-onas
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
DK1776011T3 (da) Fungicid sammensætning, indeholdende et syreamidderivat
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
GB2437009A (en) Ranking system
EP1735970A4 (en) PIPELINE PACKAGE PROCESSOR
IL176142A (en) Processes for preparing montelukast sodium
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
TW200800967A (en) Benzimidazole thiophene compounds
WO2009102707A3 (en) Substituted oxazaphosphorines
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
BRPI0815003A2 (pt) Uso de um composto, composições, compostos, uso dos mesmos, método de tratamento, melhora ou profilaxia dos sintomas de um distúrbio inflamatório.